ACARD评分:预测非缺氧性癫痫持续状态短期死亡风险
本研究基于意大利和奥地利两个多中心队列(分别为689例和569例癫痫持续状态发作),开发并验证了预测非缺氧性癫痫持续状态30天死亡风险的ACARD评分。该评分基于年龄≥75岁、意识障碍、急性中枢神经系统病因、治疗难治性和基线残疾五个独立预测因子,推导队列AUC为0.864,验证队列AUC为0.845,校准良好。
要点
- ACARD评分包含年龄≥75岁、意识障碍、急性CNS病因、治疗难治性、基线残疾五个预测因子。
- 推导队列AUC为0.864(95%CI 0.836-0.891),验证队列AUC为0.845(95%CI 0.801-0.888)。
- 该评分可用于识别非缺氧性癫痫持续状态短期死亡高危患者,辅助临床决策。
核心结论
- ACARD评分是一种简便工具,可预测非缺氧性癫痫持续状态后30天死亡风险,并识别短期死亡高危患者。
- 该评分在推导队列和验证队列中均表现出良好的区分度和校准度,可能优于现有其他评分系统。
研究设计与样本
- 多中心、多国注册队列研究,纳入意大利摩德纳连续癫痫持续状态发作(年龄≥14岁,推导队列689例)和奥地利萨尔茨堡连续发作(年龄≥18岁,验证队列569例)。
- 预设结局为癫痫持续状态起病后30天死亡率,评估年龄、性别、治疗前意识水平、发作症状学、基线残疾、病因及治疗难治性等预测因子。
主要发现
- 推导队列30天死亡率为27.3%,验证队列为11.6%。
- 独立危险因素包括:年龄≥75岁(OR 5.52,95%CI 3.45-8.83;p<0.001)、治疗前意识障碍(OR 1.76,95%CI 1.09-2.82;p=0.020)、急性原发CNS病因(OR 2.60,95%CI 1.60-4.23;p<0.001)、治疗难治性(OR 6.40,95%CI 3.91-10.46;p<0.001)、基线残疾(OR 3.53,95%CI 2.22-5.61;p<0.001)。
- 远程病因与较低的30天死亡风险独立相关(OR 0.28,95%CI 0.13-0.61;p=0.001)。
关键数值与推荐
- ACARD评分基于五个独立预测因子(年龄、意识、病因、难治性、残疾)构建,采用整数计分。
- 推导队列AUC为0.864(95%CI 0.836-0.891),验证队列AUC为0.845(95%CI 0.801-0.888),校准图显示预测值与观察值拟合良好。
临床怎么用
- ACARD评分可用于非缺氧性癫痫持续状态患者入院早期风险分层,辅助识别30天死亡高危患者。
- 评分可能有助于指导治疗强度决策和医患沟通,但需在临床实践中进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Reliable prediction of short-term mortality in status epilepticus (SE) can contribute to guide clinical decisions. Current prognostic systems achieve only acceptable predictive power and show lack of generalizability or poor calibration. We aimed to identify clinical predictors of short-term mortality in patients with nonhypoxic SE and develop a predictive score. METHODS: This was a multicenter, multinational cohort study based on registry data. Participants were consecutive episodes of SE in participants aged 14 years or older from Modena (Italy) (derivation cohort) and in participants aged 18 years or older from Salzburg (Austria) (validation cohort). The predefined outcome was 30-day mortality after the onset of SE. Age, sex, level of consciousness before treatment, semiology of SE, level of disability at baseline before SE, etiology, and treatment refractoriness were assessed. Adjusted regression coefficients of each independent predictor were transformed to produce a points-based risk scoring system. RESULTS: The Italian cohort included 689 episodes, and the Austrian cohort comprised 569 episodes of SE. In the derivation cohort, the 30-day mortality rate was 27.3%. The independent risk factors were aged 75 years or older (odds ratio [OR] 5.52, 95% CI 3.45-8.83; p < 0.001), consciousness impairment (stuporous or comatose) before SE treatment (OR 1.76, 95% CI 1.09-2.82; p = 0.020), acute etiology due to primary CNS pathology (OR 2.60, 95% CI 1.60-4.23; p < 0.001), refractoriness to treatment (OR 6.40, 95% CI 3.91-10.46; p < 0.001), and disability before SE onset (OR 3.53, 95% CI 2.22-5.61; p < 0.001); remote etiology was independently associated with a lower likelihood of 30-day mortality (OR 0.28, 95% 0.13-0.61; p = 0.001). An integer-based scoring system termed Age, Consciousness, Aetiology, Refractoriness, Disability (ACARD) was developed by combining these independent predictors. In the validation cohort, the 30-day mortality rate was 11.6%. The area under the curve of the ACARD score was 0.864 (95% CI 0.836-0.891) in the derivation cohort and 0.845 (95% CI 0.801-0.888) in the validation cohort. Calibration plot indicated good fit of predicted and observed data in both cohorts. DISCUSSION: The ACARD score is a user-friendly tool developed to predict 30-day mortality after nonhypoxic SE. It has the potential to identify participants at high risk of short-term mortality and outperform the performance of other available scoring systems.
引用
- Lattanzi S, Trinka E, Bosque-Varela P, et al. A Predictive Model for Short-Term Mortality After Status Epilepticus: The ACARD Score. Neurology. 2026. PMID: 42479996. doi:10.1212/WNL.0000000000218281
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。